1 / 1

Symposium on Biomarkers in Drug Development: From Discovery to Validation in the Omic Era

Symposium on Biomarkers in Drug Development: From Discovery to Validation in the Omic Era 9 th October 2006 at the UCD Conway Institute. Registration: Coffee/tea (10.30am-11.00am) Biomarker Discovery Session (11.00am-1.00pm) Transcriptomic Approaches Used in Safety Assessment

inga
Download Presentation

Symposium on Biomarkers in Drug Development: From Discovery to Validation in the Omic Era

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Symposium on Biomarkers in Drug Development: From Discovery to Validation in the Omic Era 9th October 2006 at the UCD Conway Institute Registration: Coffee/tea (10.30am-11.00am) Biomarker Discovery Session (11.00am-1.00pm) Transcriptomic Approaches Used in Safety Assessment Philip Hewitt, Merck, Germany Recent Applications of Protein Arrays to Biomarker Discovery Dolores Cahill, UCD Conway Institute, Ireland Glycomics and Biomarker Discovery Pauline Rudd, NIBRT, Ireland Proteomics: Expression Analysis Stephen Pennington, UCD Conway Institute, Ireland Disease-Specific Arrays: New Tool for Genomics Biomarker Discovery Vitali Proutski, Almac Diagnostics, United Kingdom Lunch (1.00pm-2.00pm): Presentation by Perkin Elmer from 1.15-1.45pm Biomarker Validation Session (2.00pm-4.00pm) Development of a Validated Clinical Assay to Determine the Methylation Status of the MGMT Gene Promoter in Glioblastoma Katia Bierau, OncoMethylome Sciences, Belgium From Proteomic Profiling to Multiplex Assay Development Huw Davies, Ciphergen Biosystems, UK Multiplexed Biomarker Assay Development for Safety Markers Pankaj Oberoi, Meso Scale Discovery, USA Tissue Microarrays: Applications in Biomarker Validation Donal Brennan, UCD Conway Institute, Ireland Route to Biomarker Validation with the FDA Frank Dieterle, Novartis Pharma, Switzerland Coffee/tea (4.00pm-4.30pm) Viewpoint Session (4.30-6.30pm) The Innovative Medicines Initiative Jørgen Dirach, Novo Nordisk, Denmark Biomarkers in Safety Assessment: The PredTox Consortium David Tweats, The Medical School, University of Wales, Swansea, UK Integration of –Omics Data: A Case Example from the Toxicological Arena Elaine Holmes, Imperial College, United Kingdom Novel Kidney Damage Biomarkers Under Evaluation in the ILSI Rat Nephrotoxicity Programme Cormac Kilty, Biotrin, Ireland Streamlining Biomarker Development: After Discovery, Before the Clinic Barry Heavey, IDA, Ireland Networking Reception, Including Hot Food (6.30pm-8.00pm) Deadline For Registration is 29th September 2006. Please e-mail karen.power@ucd.ie to register. No registration fee due to significant sponsorship from Enterprise Ireland.

More Related